TheraRadar
Clinical-Stage Companies / Genfleet Therapeutics

Genfleet Therapeutics

Pre-Approval PRO BETA
15
Total Trials
2
Phase 3
12
Phase 2
7
Recruiting
188
Score

Pipeline by Phase

Phase 3
2
Phase 2
12
Phase 1
9

Therapeutic Focus

Metastatic Pancreatic Cancer Advanced Solid Tumors Cancer PDAC CRC (Colorectal Cancer) NSCLC (Advanced Non-small Cell Lung Cancer)

Clinical Trials (15)

NCT07262567 Phase 3 RECRUITING

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Started: 12/4/2025

NCT07668752 Phase 3 RECRUITING

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

Started: 7/27/2026

NCT07554859 Phase 2 NOT YET RECRUITING

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

Started: 5/20/2026

NCT07026916 Phase 2 WITHDRAWN

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Started: 8/1/2025

NCT05386888 Phase 2 COMPLETED

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

Started: 9/9/2022

NCT07784374 Phase 2 NOT YET RECRUITING

A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

Started: 8/31/2026

NCT07259590 Phase 1 RECRUITING

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Started: 10/21/2025

NCT06500676 Phase 1 RECRUITING

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Started: 7/9/2024

NCT06375733 Phase 1 RECRUITING

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Started: 3/20/2024

NCT06898255 Phase 1 RECRUITING

A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia

Started: 4/24/2025

NCT05934513 Phase 1 RECRUITING

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Started: 9/6/2023

NCT07198321 Phase 1 NOT YET RECRUITING

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

Started: 9/22/2025

NCT05756153 Phase 1 COMPLETED

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Started: 4/25/2023

NCT04914286 Phase 1 COMPLETED

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Started: 10/20/2021

NCT07678593 Phase 1 NOT YET RECRUITING

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Started: 9/1/2026

Drug Candidates

ArmA:GFH375 Arm B:GFH375 Arm C:GFH375 GFH375 GFH018 GFH276 GFH009 GFH925 GFS202A injection GFS202A
Activity Status: Active
Last Trial Started: 9/1/2026
Last Trial Ended: 4/30/2025
Trials (12 months): 7
Completed Trials: 3
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.